Fig. 5

Correlations between the DEsrlncRNA pair-based signature and immunotherapy. A Tumor mutation burden was negatively correlated with the Riskscore. B The comparisons of 17 immune checkpoints between the two risk groups revealed that most of the markers were higher in the low-risk group. (Mann-Whitney U test’s t test, * for p < 0.05, ** for p < 0.01, and *** for p < 0.001 and ns for not significant). C Correlation analysis revealed that immune components were more enriched in the low-risk group (Spearman correlation analysis, p ≤ 0.05). (D) IPS analysis revealed that the Riskscore may present a better performance in predicting PD1 blockade therapy than CTLA4 blockade therapy. {“ctla4+ pd1+” (Mann-Whitney U test, p = 0.019) and “ctla4- pd1+” (Mann-Whitney U test, p = 0.013)}